LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 20

Search options

  1. Article ; Online: Novel therapies targeting cutaneous T cell lymphomas and their microenvironment.

    Reneau, John C / Wilcox, Ryan A

    Seminars in hematology

    2021  Volume 58, Issue 2, Page(s) 103–113

    Abstract: Cutaneous T-cell lymphomas (CTCL) are rare non-Hodgkin lymphomas with a generally indolent course managed with topical, skin-directed therapies. A small subset, however, will progress to advanced stage disease necessitating systemic therapy for disease ... ...

    Abstract Cutaneous T-cell lymphomas (CTCL) are rare non-Hodgkin lymphomas with a generally indolent course managed with topical, skin-directed therapies. A small subset, however, will progress to advanced stage disease necessitating systemic therapy for disease control. Currently approved therapies have low response rates and generally short durations of response. Novel therapies, therefore, are urgently needed to address this unmet need. In this review, the mechanisms of CTCL pathogenesis and progression, including the role of the tumor microenvironment and molecular alterations, are summarized. Based on these biologic insights, novel therapies currently under investigation and those with a strong preclinical biologic rationale including T cell and macrophage checkpoint inhibitors, epigenetic regulators, targeted antibodies, tyrosine kinase inhibitors, and apoptosis modulating therapies are discussed.
    MeSH term(s) Humans ; Lymphoma, Non-Hodgkin ; Lymphoma, T-Cell, Cutaneous/drug therapy ; Lymphoma, T-Cell, Cutaneous/pathology ; Skin Neoplasms/drug therapy ; Skin Neoplasms/pathology ; Tumor Microenvironment
    Language English
    Publishing date 2021-02-11
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 206923-4
    ISSN 1532-8686 ; 0037-1963
    ISSN (online) 1532-8686
    ISSN 0037-1963
    DOI 10.1053/j.seminhematol.2021.02.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 328: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors.

    Quadri, Iman / Reneau, John C / Hanel, Walter / Chung, Catherine G

    Frontiers in immunology

    2023  Volume 14, Page(s) 1291259

    Abstract: Mycosis fungoides (MF) and Sézary syndrome (SS) are forms of cutaneous T cell lymphoma (CTCL) that pose significant challenges in their clinical management, particularly in refractory and advanced-stage disease. With the emergence of novel therapeutic ... ...

    Abstract Mycosis fungoides (MF) and Sézary syndrome (SS) are forms of cutaneous T cell lymphoma (CTCL) that pose significant challenges in their clinical management, particularly in refractory and advanced-stage disease. With the emergence of novel therapeutic modalities however, there are increasing opportunities to exploit the current understanding of pathophysiologic mechanisms of MF/SS for treatment. This review summarizes recent advances in the treatment of MF/SS, with a focus on monoclonal antibodies, immunotherapies, and Janus kinase (JAK) inhibitors, including ongoing clinical trials.
    MeSH term(s) Humans ; Sezary Syndrome/drug therapy ; Antibodies, Monoclonal/therapeutic use ; Janus Kinase Inhibitors ; Skin Neoplasms/drug therapy ; Mycosis Fungoides/drug therapy ; Lymphoma, T-Cell, Cutaneous ; Immunotherapy
    Chemical Substances Antibodies, Monoclonal ; Janus Kinase Inhibitors
    Language English
    Publishing date 2023-11-03
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2023.1291259
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Autologous stem cell transplant in first remission for transformed indolent non-Hodgkin lymphoma: additional data to guide practice.

    Reneau, John C / William, Basem M

    British journal of haematology

    2020  Volume 191, Issue 5, Page(s) 663–665

    MeSH term(s) Hematopoietic Stem Cell Transplantation ; Humans ; Lymphoma, B-Cell ; Lymphoma, Non-Hodgkin/therapy ; Stem Cell Transplantation ; Transplantation, Autologous
    Language English
    Publishing date 2020-10-16
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.17075
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.182: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Presenting features of indolent primary cutaneous B-cell lymphomas: Distinguishing clinical and histopathologic features.

    Puccio, Jordyn / Huang, Ying / Reneau, John C / Chung, Catherine / Spaccarelli, Natalie / Dulmage, Brittany

    Clinics in dermatology

    2023  Volume 42, Issue 1, Page(s) 93–95

    MeSH term(s) Humans ; Lymphoma, B-Cell/diagnosis ; Skin Neoplasms/diagnosis ; Skin Neoplasms/pathology ; Lymphoma, T-Cell, Cutaneous
    Language English
    Publishing date 2023-12-09
    Publishing country United States
    Document type Letter
    ZDB-ID 1064149-x
    ISSN 1879-1131 ; 0738-081X
    ISSN (online) 1879-1131
    ISSN 0738-081X
    DOI 10.1016/j.clindermatol.2023.12.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Se 972: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas.

    Braunstein, Zachary / Ruiz, Miguel / Hanel, Walter / Shindiapina, Polina / Reneau, John C / Brammer, Jonathan E

    Journal of personalized medicine

    2022  Volume 12, Issue 6

    Abstract: Peripheral T-cell lymphomas (PTCLs) are a group of heterogeneous lymphomas with poor overall prognosis, particularly in the setting of relapsed/refractory PTCL. Given the limited efficacy of current therapies, several different novel therapies ... ...

    Abstract Peripheral T-cell lymphomas (PTCLs) are a group of heterogeneous lymphomas with poor overall prognosis, particularly in the setting of relapsed/refractory PTCL. Given the limited efficacy of current therapies, several different novel therapies encompassing multiple different mechanisms of action have been evaluated for relapsed and refractory PTCLs. In this review, we explore the current standard of care for relapsed/refractory PTCL, and evaluate in depth novel and emerging therapies, their scientific basis, and current trials for relapsed/refractory PTCL.
    Language English
    Publishing date 2022-06-13
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2662248-8
    ISSN 2075-4426
    ISSN 2075-4426
    DOI 10.3390/jpm12060964
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: 47-Year-Old Man With Pruritus.

    Reneau, John C / Patnaik, Mrinal M

    Mayo Clinic proceedings

    2016  Volume 91, Issue 2, Page(s) 241–245

    MeSH term(s) Aspirin/therapeutic use ; Diagnosis, Differential ; Disease Management ; Hemoglobins/analysis ; Histamine Antagonists/therapeutic use ; Humans ; Janus Kinase 2/genetics ; Male ; Middle Aged ; Paroxetine/administration & dosage ; Phlebotomy/methods ; Platelet Aggregation Inhibitors/therapeutic use ; Polycythemia Vera/blood ; Polycythemia Vera/complications ; Polycythemia Vera/diagnosis ; Polycythemia Vera/genetics ; Polycythemia Vera/therapy ; Pruritus/diagnosis ; Pruritus/drug therapy ; Pruritus/etiology ; Serotonin Uptake Inhibitors/administration & dosage ; Treatment Outcome
    Chemical Substances Hemoglobins ; Histamine Antagonists ; Platelet Aggregation Inhibitors ; Serotonin Uptake Inhibitors ; Paroxetine (41VRH5220H) ; Janus Kinase 2 (EC 2.7.10.2) ; Aspirin (R16CO5Y76E)
    Language English
    Publishing date 2016-02
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 124027-4
    ISSN 1942-5546 ; 0025-6196
    ISSN (online) 1942-5546
    ISSN 0025-6196
    DOI 10.1016/j.mayocp.2015.06.022
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.183: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions.

    Reneau, John C / Shindiapina, Polina / Braunstein, Zachary / Youssef, Youssef / Ruiz, Miguel / Farid, Saira / Hanel, Walter / Brammer, Jonathan E

    Journal of clinical medicine

    2022  Volume 11, Issue 10

    Abstract: Extranodal natural killer/T(NK/T)-cell lymphoma (ENKTL) is a rare subtype of non-Hodgkin lymphoma that typically presents with an isolated nasal mass, but a sizeable minority present with advanced stage disease and have a significantly poorer prognosis. ... ...

    Abstract Extranodal natural killer/T(NK/T)-cell lymphoma (ENKTL) is a rare subtype of non-Hodgkin lymphoma that typically presents with an isolated nasal mass, but a sizeable minority present with advanced stage disease and have a significantly poorer prognosis. Those with limited disease are standardly treated with chemotherapy and radiation while those with advanced stage disease are treated with L-asparaginase containing chemotherapy regimens. The addition of modern radiation therapy techniques and the incorporation of L-asparaginase into chemotherapy regimens have significantly improved outcomes in this disease, but relapses and death from relapsed disease remain frequent. Given the high rate of relapse, several novel therapies have been evaluated for the treatment of this disease. In this review, we explore the current standard of care for ENKTL as well as novel therapies that have been evaluated for its treatment and the biologic understanding behind these therapies.
    Language English
    Publishing date 2022-05-10
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm11102699
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Spontaneous Regression of High-Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements: Case Report and Literature Review.

    Stanoszek, Lauren M / Smith, Lauren B / Grajewski, Karen / Reneau, John C / Wilcox, Ryan / Perry, Anamarija M

    Clinical lymphoma, myeloma & leukemia

    2020  Volume 21, Issue 2, Page(s) e120–e125

    MeSH term(s) Adult ; Biopsy ; Bone Marrow/pathology ; Gene Rearrangement ; Humans ; Lymphoma, B-Cell/diagnosis ; Lymphoma, B-Cell/genetics ; Lymphoma, B-Cell/pathology ; Male ; Neoplasm Grading ; Positron Emission Tomography Computed Tomography ; Proto-Oncogene Proteins c-bcl-2/genetics ; Proto-Oncogene Proteins c-myc/genetics ; Remission, Spontaneous
    Chemical Substances BCL2 protein, human ; MYC protein, human ; Proto-Oncogene Proteins c-bcl-2 ; Proto-Oncogene Proteins c-myc
    Language English
    Publishing date 2020-09-23
    Publishing country United States
    Document type Case Reports ; Journal Article ; Review
    ZDB-ID 2540992-X
    ISSN 2152-2669 ; 2152-2650
    ISSN (online) 2152-2669
    ISSN 2152-2650
    DOI 10.1016/j.clml.2020.09.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5903: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: CD3e-immunotoxin spares CD62L

    Kim, Shihyoung / Shukla, Rajni Kant / Yu, Hannah / Baek, Alice / Cressman, Sophie G / Golconda, Sarah / Lee, Ga-Eun / Choi, Hyewon / Reneau, John C / Wang, Zhirui / Huang, Christene A / Liyanage, Namal P M / Kim, Sanggu

    Frontiers in immunology

    2022  Volume 13, Page(s) 1011190

    Abstract: CD3-epsilon(CD3e) immunotoxins (IT), a promising precision reagent for various clinical conditions requiring effective depletion of T cells, often shows limited treatment efficacy for largely unknown reasons. Tissue-resident T cells that persist in ... ...

    Abstract CD3-epsilon(CD3e) immunotoxins (IT), a promising precision reagent for various clinical conditions requiring effective depletion of T cells, often shows limited treatment efficacy for largely unknown reasons. Tissue-resident T cells that persist in peripheral tissues have been shown to play pivotal roles in local and systemic immunity, as well as transplant rejection, autoimmunity and cancers. The impact of CD3e-IT treatment on these local cells, however, remains poorly understood. Here, using a new murine testing model, we demonstrate a substantial enrichment of tissue-resident Foxp3+ Tregs following CD3e-IT treatment. Differential surface expression of CD3e among T-cell subsets appears to be a main driver of Treg enrichment in CD3e-IT treatment. The surviving Tregs in CD3e-IT-treated mice were mostly the CD3e
    MeSH term(s) Mice ; Animals ; Immunotoxins ; T-Lymphocytes, Regulatory ; Lymphocyte Count ; T-Lymphocyte Subsets ; Autoimmunity
    Chemical Substances Immunotoxins
    Language English
    Publishing date 2022-10-26
    Publishing country Switzerland
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2022.1011190
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma.

    Hanel, Walter / Shindiapina, Polina / Bond, David A / Sawalha, Yazeed / Epperla, Narendranath / Voorhees, Timothy / Welkie, Rina Li / Huang, Ying / Behbehani, Gregory K / Zhang, Xiaoli / McLaughlin, Eric / Chan, Wing K / Brammer, Jonathan E / Jaglowski, Samantha / Reneau, John C / Christian, Beth A / William, Basem M / Cohen, Jonathon B / Baiocchi, Robert A /
    Maddocks, Kami / Blum, Kristie A / Alinari, Lapo

    Cancers

    2023  Volume 15, Issue 5

    Abstract: Background: Relapsed or refractory classical Hodgkin lymphoma (cHL) remains a difficult treatment challenge. Although checkpoint inhibitors (CPI) have provided clinical benefit for these patients, responses are generally not durable, and progression ... ...

    Abstract Background: Relapsed or refractory classical Hodgkin lymphoma (cHL) remains a difficult treatment challenge. Although checkpoint inhibitors (CPI) have provided clinical benefit for these patients, responses are generally not durable, and progression eventually occurs. Discovering combination therapies which maximize the immune response of CPI therapy may overcome this limitation. We hypothesized that adding ibrutinib to nivolumab will lead to deeper and more durable responses in cHL by promoting a more favorable immune microenvironment leading to enhanced T-cell-mediated anti-lymphoma responses.
    Methods: We conducted a single arm, phase II clinical trial testing the efficacy of nivolumab in combination with ibrutinib in patients ≥18 years of age with histologically confirmed cHL who had received at least one prior line of therapy. Prior treatment with CPIs was allowed. Ibrutinib was administered at 560 mg daily until progression in combination with nivolumab 3 mg/kg IV every 3 weeks for up to 16 cycles. The primary objective was complete response rate (CRR) assessed per Lugano criteria. Secondary objectives included overall response rate (ORR), safety, progression free survival (PFS), and duration of response (DoR).
    Results: A total of 17 patients from two academic centers were enrolled. The median age of all patients was 40 (range 20-84). The median number of prior lines of treatment was five (range 1-8), including 10 patients (58.8%) who had progressed on prior nivolumab therapy. Most treatment related events were mild (<Grade 3) and expected from the individual side effect profiles of ibrutinib and nivolumab. In the intent to treat population (<br />Conclusions: Combined nivolumab and ibrutinib led to a CRR of 29.4% in R/R cHL. Although this study did not meet its primary efficacy endpoint of a CRR of 50%, likely due to enrollment of heavily pretreated patients including over half of who had progressed on prior nivolumab treatment, responses that were achieved with combination ibrutinib and nivolumab therapy tended to be durable even in the case of prior progression on nivolumab therapy. Larger studies investigating the efficacy of dual BTK inhibitor/immune checkpoint blockade, particularly in patients who had previously progressed on checkpoint blockade therapy, are warranted.
    Language English
    Publishing date 2023-02-24
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers15051437
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top